The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Flagged first, then by citations
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 601–700 of 1,001
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Cheon, E. J., Cha, D. H., Cho, S. K., Noh, H.-M., Park, S., Kang, S., Gee, H. Y., & Lee, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.011 · Cited by 9
Clearfield, M. B., Davis, G. E., Weis, J., Gayer, G. G., & Shubrook, J. H. (2018) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2018.157 · Cited by 10
Salahuddin, T., Kittelson, J. K., Tardif, J., Shah, P. K., OLSSON, A. G., Nicholls, S. J., Leitersdorf, E., Leiter, L. A., Kallend, D. G., Black, D. M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.12.003 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
Cochran, B. J., Manandhar, B., & Rye, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_9 · Cited by 8
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Yelamanchili, D., Gillard, B. K., Gotto, A. M., Cainzos‐Achirica, M., Nasir, K., Remaley, A. T., Rosales, C., & Pownall, H. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100707 · Cited by 8
Wadowski, P. P., Lee, S., Kopp, C. W., Koppensteiner, R., Panzer, S., & Gremmel, T. (2018) · Angiology · doi:10.1177/0003319718760074 · Cited by 8
Metabolismus und Funktion der Lipoproteine hoher Dichte (HDL)
Jomard, A., & Osto, E. (2019) · Praxis · doi:10.1024/1661-8157/a003241 · Cited by 8
The Rise and Fall “ing” of the HDL Hypothesis
Feghaly, J., & Mooradian, A. D. (2020) · Drugs · doi:10.1007/s40265-020-01265-4 · Cited by 8
Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice
Palmisano, B. T., Anozie, U., Yu, S., Neuman, J. C., Zhu, L., Edington, E. M., Luu, T. N., & Stafford, J. M. (2020) · Lipids · doi:10.1002/lipd.12271 · Cited by 8
Bao, J., Zheng, S., Huang, J., Xie, X., Zhang, J., Yang, S., Wu, X., & Zhang, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1024 · Cited by 8
Vexed causal inferences in nutritional epidemiology—call for genetic help
Ohukainen, P., Virtanen, J. K., & Ala‐Korpela, M. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab152 · Cited by 8
What is the Optimal Low-Density Lipoprotein Cholesterol?
Gagel, A., Zghyer, F., Samuel, C., & Martin, S. S. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.005 · Cited by 8
Type 2 Diabetes and HDL Dysfunction: A Key Contributor to Glycemic Control
Rotllán, N., Julve, J., & Escolá‐Gil, J. C. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230201124125 · Cited by 8
Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein
Ji, A., Trumbauer, A. C., Noffsinger, V. P., de Beer, F. C., Webb, N. R., Tannock, L. R., & Shridas, P. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100365 · Cited by 8
Anacetrapib as a potential cardioprotective strategy
Bartolo, B. A. D., & Nicholls, S. J. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114104 · Cited by 8
Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials
Filippatos, T. D., Panagiotopoulou, T., Tzavella, E., & Elisaf, M. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418757011 · Cited by 8
Heier, M., Ofstad, A. P., Borja, M. S., Brunborg, C., Endresen, K., Gullestad, L. L., Birkeland, K. I., Johansen, O. E., & Oda, M. N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.005 · Cited by 8
Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
Mayr, M., Gerszten, R. E., & Kiechl, S. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.040 · Cited by 9
Maki, K. C. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.016 · Cited by 8
Liu, R., & Cheng, W. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14754 · Cited by 7
Microenvironments‐Targeted Nanomaterials for Atherosclerosis Therapy
Song, C., Ling, H., Yang, G., & Ding, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202421512 · Cited by 7
Wang, X., Li, X., Liu, K., Yi, K., Yang, Y., Wu, D., & Liu, X. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100836 · Cited by 7
HDL-C: Helpful, harmful, hopeful, or guilty by association
McLean, P., Mathew, D., Chandrasekhar, S. A., Guynn, N., Razavi, A. C., Quyyumi, A. A., Mehta, A., & Sperling, L. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.017 · Cited by 7
Naim, M. A. A. Z., Sumida, K., Streja, E., Thomas, F., Davis, R. L., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2026) · Drugs · doi:10.1007/s40265-025-02275-w · Cited by 8
Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities
Pinto, G., & Fragasso, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2118576 · Cited by 8
Noflatscher, M., Hunjadi, M., Schreinlechner, M., Sommer, P., Lener, D., Theurl, M., Kirchmair, R., Bauer, A., Ritsch, A., & Marschang, P. (2023) · Biomedicines · doi:10.3390/biomedicines11071918 · Cited by 7
The pathophysiology of excess plasma-free cholesterol
Gillard, B. K., Rosales, C., Gotto, A. M., & Pownall, H. J. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000899 · Cited by 7
Shokrieh, A., Mirzaei, A. H., Mao, L., Shokrieh, M. M., & Wei, Z. (2023) · Nano Research · doi:10.1007/s12274-023-6211-z · Cited by 7
Kenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 8
PCSK9 inhibitor valuation: A science‐based review of the two recent models
Baum, S. J., & Cannon, C. P. (2018) · Clinical Cardiology · doi:10.1002/clc.22924 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
Mafham, M. M., Bowman, L. J., Haynes, R., & Armitage, J. (2019) · Diabetologia · doi:10.1007/s00125-019-05049-8 · Cited by 6
Dyslipidemia: Current Perspectives and Implications for Clinical Practice
Majanović, S. K., Cvijanović, O., Detel, D., Jovanović, G. K., Bakula, M., Rahelić, D., Čaljkušić‐Mance, T., Šoić-Vranić, T., & Cvek, S. Z. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98386 · Cited by 9
Manichaikul, A. W., Lin, H., Kang, C., Yang, C., Rich, S. S., Taylor, K. D., Guo, X., Rotter, J. I., Johnson, W. C., Cornell, E. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03304-0 · Cited by 7
Wei, M., Li, F., Guo, K., & Yang, T. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s395207 · Cited by 7
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 9
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice
Maki, K. C., & Dicklin, M. R. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0725-y · Cited by 7
Biomarkers in drug development
Schuck, R. N., Delfino, J. G., Leptak, C., & Wagner, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00029-x · Cited by 7
Lower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7
Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
Ready, J. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01540 · Cited by 7
Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia
Inazu, A. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22037 · Cited by 8
Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies
Al‐Horani, R. A., Selico-Dunn, A. C., & Smith, E. L. S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07810-1 · Cited by 9
Emara, A., Gadelmawla, A. F., Awashra, A., Rifai, M. K., Elgendy, M. S., Diaa, A., Emara, M. R., Odat, R. M., Assaassa, A., & Shubietah, A. R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70316 · Cited by 6
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults
Bagherikholenjani, F., Shahidi, S., Vaseghi, G., Ashoorion, V., Sarrafzadegan, N., Siavash, M., Heidarpour, M., Shahidi, S., Sadeghi, M., Mohammadifard, N., et al. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_318_23 · Cited by 8
Hashem, C., Altin, S. E., Guyton, J. R., & Boden, W. E. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.009 · Cited by 7
Zhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 6
HDL-replacement therapy: From traditional to emerging clinical applications
Sirtori, C. R., Cincotto, G., Castiglione, S., & Pavanello, C. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.02.001 · Cited by 6
Sisson, E. M., Pamulapati, L. G., Bucheit, J. D., Kelly, M. S., & Dixon, D. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2074 · Cited by 6
Residual Cardiovascular Risk—Is Inflammation the Primary Cause?
Schade, D. S., & Eaton, R. P. (2018) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2018.81007 · Cited by 6
Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
Grabie, M., Tai, C.-H., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000245 · Cited by 6
Ueland, T., Roland, M. C. P., Michelsen, A. E., Godang, K., Aukrust, P., Henriksen, T., Bollerslev, J., & Lekva, T. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz119 · Cited by 6
Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population: Insights From MESA
Hunter, W. G., Smith, A., Pinto, R. C., Saldanha, S., Gangwar, A., Pahlavani, M., Deodhar, S., Wilkins, J. T., Pandey, A., Herrington, D. M., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318222 · Cited by 6
Liberale, L., Montecucco, F., & Bonaventura, A. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12856 · Cited by 7
Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease
Buckley, L. F., Carbone, S., Aldemerdash, A. M., Fatani, N., & Fanikos, J. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.08.019 · Cited by 6
Lipids: a personal view of the past decade
Katsiki, N., & Mikhailidis, D. P. (2018) · HORMONES · doi:10.1007/s42000-018-0058-9 · Cited by 6
Johns, D. G., LeVoci, L., Krsmanovic, M. L., Lu, M., Hartmann, G., Xu, S. S., Wang, S.-P., Chen, Y., Bateman, T. J., & Blaustein, R. O. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084525 · Cited by 6
Whyte, M. (2019) · JRSM Cardiovascular Disease · doi:10.1177/2048004019869736 · Cited by 6
Ferrières, J., Lautsch, D., Bramlage, P., Horack, M., Baxter, C. A., Ambegaonkar, B. M., Toth, P. P., Poh, K. K., Ferrari, G. M. D., & Gitt, A. K. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.05.013 · Cited by 6
Extra- versus intracranial atherosclerosis: two facets of the same problem
Tanashyan, M. М., Лагода, О. В., Раскуражев, А. А., Annushkin, V. A., Mazur, A. S., & Sinitsyn, I. A. (2022) · Russian neurological Journal · doi:10.30629/2658-7947-2022-27-3-11-19 · Cited by 6
Zheng, B., Goto, S., Clementi, R. A., Feaster, J., Duffy, D., Dalitz, P., Airey, J., Korjian, S., Tortorici, M. A., Roberts, J., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13361 · Cited by 6
Role of Payers in the Development of Cardiovascular Therapeutics
Zannad, F. M., García, M. D. L. A. A., BORER, J. S., Stough, W. G., Clutton-Brock, T. H., Rosenberg, Y., & Packer, M. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.027 · Cited by 6
Gordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.11.377747 · Cited by 6
Laufs, U., & Speer, T. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab889 · Cited by 6
Hussain, S. M., & McNeil, J. J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07703-3 · Cited by 6
Li, X., Xue, H., Yang, S., Li, Y., Dai, C., Mai, J., Li, J. B., Li, Y., & Bao, H. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510560 · Cited by 5
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2511 · Cited by 5
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
Lan, N. S. R., & Watts, G. F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01281-3 · Cited by 5
Wu, X., He, Z., Sun, R., Xie, X., Chen, Q., Wang, J., Bao, J., Huang, J., Jiang, Y., Zhang, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-948 · Cited by 4
Altered lipid metabolism and serum lipids in chronic kidney disease
Vaziri, N. D., Moradi, H., & Zhao, Y.-Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00009-4 · Cited by 5
HDL-Based Therapy: Vascular Protection at All Stages
Poznyak, A. V., Sukhorukov, V. N., Eremin, I. I., Nadelyaeva, I. I., Gutyrchik, N. A., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11030711 · Cited by 5
A Polynesian-specific missense CETP variant alters the lipid profile
Moors, J., Krishnan, M., Sumpter, N., Takei, R., Bixley, M., Cadzow, M. J., Major, T. J., Phipps‐Green, A. J., Topless, R., Merriman, M. E., et al. (2023) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2023.100204 · Cited by 8
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk
Bilgic, S., Remaley, A. T., & Sniderman, A. D. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000905 · Cited by 5
Chen, X., Xiang, Y.-F., Cai, X., Chen, J., Lin, X., Lin, B., Liang, W.-J., Zhou, G., Guo, Y., & Lin, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131773 · Cited by 5
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 5
Yarmolinsky, J., Lee, M. A., Lau, E., Moratalla-Navarro, F., Vincent, E. E., Li‐Gao, R., Rensen, P. C. N., van Dijk, K. W., Tsilidis, K. K., Sangphukieo, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf137 · Cited by 5
Atherogenic lipoproteins as treatment targets
Catapano, A. L. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.221 · Cited by 5
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
CETP inhibition and HDL: what is the trial REVEALing?
Badimón, L. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx240 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Novel approaches to lipid-lowering therapy
Brozin, D., & Raal, F. J. (2018) · South African Medical Journal · doi:10.7196/samj.2017.v108i4.13234 · Cited by 5
Ferrari, G. M. D., Perna, G. P., Nicosia, A., Guasti, L., Casu, G., Cuccia, C., Picco, F., Strazzella, C., Totaro, R., Cercone, S., et al. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000680 · Cited by 5
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
Naeem, F., McKay, G. A., & Fisher, M. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.180 · Cited by 5
Lee, E.-J., Kwon, S. U., Park, J.-H., Kim, Y., Hong, K., Yu, S., Hwang, Y., Lee, J. S., Lee, J., Rha, J., et al. (2020) · Journal of Stroke · doi:10.5853/jos.2019.02551 · Cited by 5
Jung, D. S., Son, Y., Shin, J. M., Won, H. J., Le, T. T., Jung, S. H., Lee, C., & Nho, C. W. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000490 · Cited by 5
Jin, J., Cao, Y., Wu, L., You, X.-D., Guo, N., Guo, Y., Wu, N., Zhu, C., Xu, R., Liu, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-037340 · Cited by 7
Zou, J., Qi, S., Sun, X., Zhang, Y., Wang, Y., Li, Y., Zhao, Z., & Lei, D. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116909 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Seo, W., Hosseini, M. B., Bang, O. Y., & Liebeskind, D. S. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00009 · Cited by 5
Levinson, S. S. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.11.001 · Cited by 5
Multitrait genetic-phenotype associations to connect disease variants and biological mechanismsPreprint
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Vaysse, A., Lechat, P., Ménager, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.172999 · Cited by 5
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Association of high-density lipoprotein cholesterol with the top 10 causes of death
Shi, S., Lin, Z., Song, Y., Ye, Z., Song, C., & Dou, K. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf749 · Cited by 6
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
